Advertisement

Topics

Positive Phase III Data for Novo’s Diabetes Drug

10:40 EDT 17 Aug 2017 | Drug Discovery Development

The head-to-head comparison pitted Novo Nordisk’s semaglutide against Eli Lilly’s dulaglutide (Trulicity). The SUSTAIN 7 trial results demonstrated that people with type 2 diabetes treated with once-weekly semaglutide experienced superior reduction in HbA1c and body weight compared to treatment with dulaglutide.
Staff Author: 

Original Article: Positive Phase III Data for Novo’s Diabetes Drug

NEXT ARTICLE

More From BioPortfolio on "Positive Phase III Data for Novo’s Diabetes Drug"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...